Article
Emerging Weapons Against Generics
Authors
-
- Name
- Person title
- Senior Principal
Health Law 360 article written by Terry Mahn, April 12, 2007
“Emerging Weapons Against Generics”
by Terry Mahn
Health Law 360
April 12, 2007
Since enactment of the Hatch-Waxman Act in 1984, the U.S. Food and Drug Administration has been at the vortex of pharmaceutical patent enforcement.
As overseer of the so-called Orange Book, where pioneer patents are listed to provide notice to generics as well as to potentially block their market entry, the FDA has been pulled into patent disputes, both small and large, for over two decades.
Ill-equipped to mediate such disputes and reluctant to take sides, the FDA was forced nonetheless to adopt reforms in 2003 to eliminate various Orange Book “strategies” which generics had claimed were stifling drug competition.
Since then, pioneer manufacturers have responded with new and increasingly clever ways of asserting their drug patents against generics manufacturers.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.